This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Day One Biopharmaceuticals (DAWN) Panoramica del titolo
Day One Biopharmaceuticals, Inc. è un'azienda biofarmaceutica in fase commerciale che si occupa dell'identificazione, dello sviluppo e della commercializzazione di farmaci per le malattie dell'infanzia e dell'adulto con uguale intensità negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
DAWN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Day One Biopharmaceuticals, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$21.53 |
| Massimo di 52 settimane | US$21.53 |
| Minimo di 52 settimane | US$5.64 |
| Beta | -1.75 |
| Variazione di 1 mese | 0.61% |
| Variazione a 3 mesi | 80.17% |
| Variazione di 1 anno | 178.17% |
| Variazione a 3 anni | 73.63% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -16.84% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Apr 13
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.Aggiornamento della narrazione • Mar 29
DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.Aggiornamento della narrazione • Mar 15
DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.Recent updates
Aggiornamento della narrazione • Apr 13
DAWN: Servier Cash Offer Will Define Deal Outcome And Future Pipeline Path
Analysts have reset their Day One Biopharmaceuticals price targets to $21.50, generally aligning with Servier's agreed $21.50 per share cash acquisition price. They are also shifting ratings to more neutral stances, as upside potential is now seen as capped by the deal terms.Aggiornamento della narrazione • Mar 29
DAWN: Servier Cash Offer Will Frame Deal Completion And Pipeline Optionality
Analysts have reset their price targets on Day One Biopharmaceuticals to $21.50, a move of up to $3.00 from prior estimates. They are aligning their models with the agreed $21.50 per share cash acquisition by Servier and see limited scope for additional upside from standalone growth assumptions.Aggiornamento della narrazione • Mar 15
DAWN: Servier Cash Offer Will Define Future Upside And Downside Potential
The analyst price target for Day One Biopharmaceuticals has shifted from $22.25 to $21.50, with analysts aligning their views to the agreed $21.50 per share cash acquisition price from Servier and adjusting their assumptions around revenue growth, profit margins, discount rate, and future P/E accordingly. Analyst Commentary Following the Servier agreement, Street research has largely converged around the US$21.50 cash offer, with multiple firms cutting ratings to Neutral or Hold and aligning price targets with the acquisition price.
Aggiornamento della narrazione • Mar 01
DAWN: Ojemda Franchise And Mersana Integration Will Recast Future Earnings Power
Analysts nudged their price target on Day One Biopharmaceuticals up by $1 to $30, reflecting updated assumptions around revenue growth, profitability, and future P/E, now that recent Street research has incorporated both the latest quarterly results and ongoing Ojemda development plans. Analyst Commentary Bullish analysts are framing the latest price target move to $30 as part of a broader, constructive view on Day One Biopharmaceuticals, grounded in updated revenue, profitability, and P/E assumptions around the Ojemda franchise and recent quarterly results.Seeking Alpha • Feb 27
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Summary Day One Biopharmaceuticals, Inc.'s Q4 '25 came with net product revenues of $52.8M, up 36% from the prior quarter. DAWN's 2026 guidance for U.S. net product revenues of $225M-$250M implies 50% growth over 2025 at the midpoint of that guidance. Key catalysts include clinical readouts from Emi-Le and DAY-301 in 2026. A readout from FIREFLY-2 could come in mid-2027. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Feb 15
DAWN: Future Cash Flows From Mersana Acquisition Will Drive Upside Potential
Analysts raised their fair value estimate for Day One Biopharmaceuticals by $1 to $17.00, citing updated assumptions that combine higher revenue expectations, a higher future P/E, and a slightly higher discount rate. Analyst Commentary Recent Street research on Day One Biopharmaceuticals reflects a mix of optimism about the company’s potential and caution about execution risks and valuation.Aggiornamento della narrazione • Feb 01
DAWN: Mersana Acquisition Will Recast Pipeline Risk Profile And Future Earnings Power
Narrative Update: Day One Biopharmaceuticals Analysts have adjusted their price target on Day One Biopharmaceuticals from US$27 to US$29, reflecting updated views on the Mersana acquisition, revised assumptions for future revenue growth and profit margins, and a higher future P/E multiple, even as some recent research has featured lower individual price targets. Analyst Commentary Recent Street research around Day One Biopharmaceuticals has centered on the acquisition of Mersana Therapeutics and how that deal reshapes the company’s pipeline, risk profile, and potential long term earnings power.Articolo di analisi • Jan 21
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Despite an already strong run, Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shares have been powering on, with a...Aggiornamento della narrazione • Jan 08
DAWN: Mersana Acquisition And OJEMDA Durability Data Will Reshape Pipeline Risk Profile
Analysts have adjusted their price target on Day One Biopharmaceuticals from US$34.00 to US$27.00, citing updated assumptions on growth, margins and future P/E, along with support for the recently announced, higher cost acquisition of Mersana Therapeutics as a way to diversify the pipeline beyond OJEMDA. Analyst Commentary Bullish analysts are framing the Mersana deal as a sign that Day One is willing to pay up to secure assets that fit tightly with its focus on targeted oncology, even if the acquisition cost of up to US$285 million looks full on headline terms.Aggiornamento della narrazione • Dec 23
DAWN: Mersana Deal Will Diversify ADC Platform And Support Future Upside
Analysts nudged their price target on Day One Biopharmaceuticals slightly higher to $22.25 per share, citing cautious optimism that the $285 million Mersana acquisition could diversify the pipeline beyond OJEMDA and enhance long term growth prospects despite its premium valuation. Analyst Commentary Bullish Takeaways Bullish analysts view the acquisition of Mersana as a strategic way to add a second antibody drug conjugate, Emi Le, alongside PTK7.Articolo di analisi • Dec 19
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Aggiornamento della narrazione • Dec 09
DAWN: Mersana Acquisition Will Diversify ADC Pipeline And Support Long Term Upside
Analysts slightly raised their price target for Day One Biopharmaceuticals to $22.25 per share, citing the strategically bold, though expensive, acquisition of Mersana Therapeutics as a catalyst for pipeline diversification beyond OJEMDA and as a potential source of long term value. Analyst Commentary Analyst reactions to the Mersana deal highlight a mix of strategic enthusiasm and execution risk, with many viewing the transaction as a meaningful but high stakes swing for Day One's long term growth profile and valuation.Aggiornamento della narrazione • Nov 25
DAWN: Acquisition of ADC Candidate Will Broaden Pipeline and Patient Reach
Analysts have lowered their price target for Day One Biopharmaceuticals from $24.25 to $22.25. They cited uncertainty over the recent $285 million Mersana acquisition, despite noting improved profit margin and revenue projections.Articolo di analisi • Nov 08
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Fly 29% But Investors Aren't Buying For Growth
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shares have continued their recent momentum with a 29% gain in the...Articolo di analisi • Nov 07
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) just released its latest quarterly results and things are looking...Articolo di analisi • Sep 06
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30%
Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shareholders would be excited to see that the share price has had a...Aggiornamento della narrazione • Aug 07
Expanded Clinical Indications And European Approvals Will Shape Future Oncology
Despite a substantially improved net profit margin and a lower future P/E ratio indicating enhanced profitability and valuation, the consensus analyst price target for Day One Biopharmaceuticals has been reduced from $26.25 to $24.00. Valuation Changes Summary of Valuation Changes for Day One Biopharmaceuticals The Consensus Analyst Price Target has fallen from $26.25 to $24.00.Articolo di analisi • Jul 18
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Nuova narrazione • Apr 29
FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options
FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma.Seeking Alpha • Feb 03
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer
Summary Day One Biopharma's OJEMDA received FDA accelerated approval in 2024 for relapsed/refractory BRAF-altered pediatric low-grade glioma, with strong Phase 2 trial results and ongoing Phase 3 studies. Despite OJEMDA's 2024 sales reaching $57.2 million, market concerns persist due to its small patient population and competition from Novartis' BRAF-targeted therapy. Day One's pipeline includes DAY301, targeting PTK7 in solid tumors, but its early-stage development suggests FDA approval is years away. Given current market conditions and future catalysts, I rate Day One Biopharma as a Hold, with potential for a more bullish outlook based on revenue growth and pipeline progress. Read the full article on Seeking AlphaSeeking Alpha • Jan 07
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Summary Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk. Potential peak sales of $800M-$1B and a valuation upside of 215%-294%, making DAWN a compelling investment opportunity. Read the full article on Seeking AlphaArticolo di analisi • Nov 04
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Celebrations may be in order for Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN ) shareholders, with the analysts...Articolo di analisi • Jul 12
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Jul 07
Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Summary Today, we circle back to Day One Biopharmaceuticals as the company's stock has dropped some even after its first FDA approval in late April. Analysts are optimistic about Day One Biopharmaceuticals, with numerous buy ratings and price targets ranging from $33 to $40 a share. The stock currently trades for less than $14/share. Despite the FDA approval, there is still some uncertainty as there are several moving parts to this story. An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 24
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Summary Day One Biopharmaceuticals, Inc. secured accelerated approval for its lead drug tovorafenib yesterday in pediatric brain cancer. The drug will be marketed and sold as Ojemda. Ojemda will be able to address a larger patient population that Novartis' currently approved Mekinist - perhaps 2-3k patients per annum. That opens up a market opportunity of ~$1bn, and peak revenue opportunity of $500 - $600m, I estimate. As a loss-making company that must complete a post-marketing study of Ojemda before full approval is granted, current market cap valuation of ~$1.4bn seems fair. Read the full article on Seeking AlphaArticolo di analisi • Mar 18
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 01
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Summary Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to fund operations through 2026, and is progressing through clinical trials with promising results. Day One's lead product candidate, tovorafenib, has the potential to redefine the standard of care for pediatric low-grade glioma, pending regulatory approval. Read the full article on Seeking AlphaArticolo di analisi • Dec 04
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Jun 19
We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendimenti per gli azionisti
| DAWN | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 0.3% | 2.4% | 1.1% |
| 1Y | 178.2% | 34.6% | 28.7% |
Ritorno vs Industria: DAWN ha superato il US Biotechs che ha restituito 34.6 % nell'ultimo anno.
Rendimento vs Mercato: DAWN ha superato il mercato US che ha restituito 28.7 % nell'ultimo anno.
Volatilità dei prezzi
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di DAWN è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di DAWN è aumentata da 14% a 21% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2018 | 178 | Jeremy Bender | dayonebio.com |
Day One Biopharmaceuticals, Inc. è una società biofarmaceutica in fase di sviluppo commerciale, impegnata nell'identificazione, nello sviluppo e nella commercializzazione di farmaci per malattie infantili e adulte con uguale intensità negli Stati Uniti. Il candidato principale dell'azienda è tovorafenib, un inibitore della chinasi del fibrosarcoma di tipo II, orale e a rapida accelerazione cerebrale, che è in fase di sperimentazione clinica di Fase II per i pazienti pediatrici con glioma di basso grado recidivato o refrattario; e Ipsen, un pLGG alterato dal raf di prima linea che è in fase di sperimentazione clinica di Fase III. L'azienda sta inoltre sviluppando DAY301, un ADC mirato a PTK7 composto da un nuovo anticorpo monoclonale umanizzato anti-PTK7 immunoglobulina G1 coniugato con un inibitore della topoisomerasi I attraverso un linker altamente stabile e idrofilo modificabile con valina-alanina (VA) per il trattamento di pazienti con tumori solidi avanzati; e Emi-Le, un coniugato anticorpo-farmaco che ha come bersaglio B7- H4 coniugato con un payload anti-tubulina auristatina come componente di una piattaforma proprietaria di linker-payload sviluppata da Mersana Therapeutics, che è in fase di sperimentazione clinica di Fase 1 per il trattamento del carcinoma mammario, del carcinoma ovarico, del carcinoma endometriale e del carcinoma adenoide-cistico (ACC).
Day One Biopharmaceuticals, Inc. Riepilogo dei fondamenti
| DAWN statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$2.22b |
| Utili (TTM) | -US$107.32m |
| Ricavi(TTM) | US$158.18m |
14.1x
Rapporto P/S-20.7x
Rapporto P/EDAWN è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| DAWN Conto economico (TTM) | |
|---|---|
| Ricavi | US$158.18m |
| Costo del fatturato | US$17.21m |
| Profitto lordo | US$140.97m |
| Altre spese | US$248.29m |
| Utili | -US$107.32m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.04 |
| Margine lordo | 89.12% |
| Margine di profitto netto | -67.85% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato DAWN nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/25 14:31 |
| Prezzo dell'azione a fine giornata | 2026/04/22 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Day One Biopharmaceuticals, Inc. è coperta da 5 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |